Mink Therapeutics doses first patient in Phase 2 agenT-797 acute lung injury trial

MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc.

INKT

0.00
  • Mink Therapeutics dosed the first patient in a randomized Phase 2 trial of agenT-797 for severe acute lung injury meeting global ARDS criteria.
  • Study compares agenT-797 with standard of care versus placebo with standard of care in critically ill ICU patients.
  • Results have not been presented; preliminary data are expected in the second half of 2026.
  • Trial aims to show whether the therapy can improve ICU recovery and survival outcomes in a setting with no mortality-reducing treatments.
  • Program expands the company’s iNKT cell platform into critical care, with U.S. IND-backed plans to add sites.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.